Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the startup of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University.
Anthem, Humana and UnitedHealth stocks have outperformed the tech giant's parent Alphabet over the past decade. U.S. insurers benefit from near-monopolies in many regions. Americans have few choices among hospitals too. Maybe Big Health is a better antitrust target than Big Tech.
The chipmaker is buying Xilinx for $35 bln. The $9 bln premium is worth more than three times the net present value of savings from the combination. CEO Lisa Su’s record is good though, so there may be some merit to the deal. At a minimum it puts Intel in a more difficult place.
A deal between two Texas drillers – involving a father and son – may be in the works. It looks like a bailout of sorts, so convincing outsiders of a fair deal will be hard. Other conflicts in shale M&A, like executive pay, loom large. Texas may be big, but the oil club is small.